Mindwalk Holdings Corp. (DE:TQB0)
NASDAQ:TQB0
TQB0 Stock Chart & Stats
€0.91
-€0.01(-2.24%)
At close: 4:00 PM EST
€0.91
-€0.01(-2.24%)
Day’s Range― - ―
52-Week Range€0.22 - €2.80
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.12K
Market Cap
€43.98M
Enterprise Value€60.47M
Total Cash (Recent Filing)€14.18M
Total Debt (Recent Filing)€3.55M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Jul 23, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding46,711,864
10 Day Avg. Volume854
30 Day Avg. Volume1,118
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.85
Price to Sales (P/S)0.83
P/FCF Ratio-2.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.28Price Target Upside370.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.23
Revenue Forecast (FY)€13.95M
Bulls Say, Bears Say
Bulls Say
AI Drug Discovery PositioningLensAI's HYFT-based platform positions the company to capture demand from pharmaceutical developers seeking AI-driven drug discovery tools, supporting customer expansion and higher recurring revenue potential.
SaaS Revenue TransitionSigning of the first enterprise LensAI SaaS contract with a major pharmaceutical client shifts revenue toward predictable subscription streams and validates the proprietary HYFT architecture, potentially improving revenue visibility and margins.
Vaccine Preclinical ProgressIn vivo immunization results showing antibody responses to a conserved epitope in the dengue program support advancement to pan-serotype testing and increase attractiveness to development and commercial partners.
Bears Say
Clinical And Execution RiskCommercial and execution setbacks in advancing preclinical programs or converting SaaS pilots into broader contracts could delay revenue growth and pressure the stock.
Competitive Landscape RiskCompetition from established pharmaceutical companies and other AI-enabled drug discovery firms could limit market share for LensAI and reduce upside from new product offerings.
Legal And Intellectual Property RiskIntellectual property disputes or other legal issues could result in costly litigation or licensing limitations that harm valuation and derail partnership discussions.
MindWalk Holdings News
TQB0 FAQ
What was Mindwalk Holdings Corp.’s price range in the past 12 months?
Mindwalk Holdings Corp. lowest stock price was €0.22 and its highest was €2.80 in the past 12 months.
What is Mindwalk Holdings Corp.’s market cap?
Mindwalk Holdings Corp.’s market cap is €43.98M.
When is Mindwalk Holdings Corp.’s upcoming earnings report date?
Mindwalk Holdings Corp.’s upcoming earnings report date is Jul 23, 2026 which is in 105 days.
How were Mindwalk Holdings Corp.’s earnings last quarter?
Mindwalk Holdings Corp. released its earnings results on Mar 12, 2026. The company reported -€0.051 earnings per share for the quarter, missing the consensus estimate of -€0.034 by -€0.016.
Is Mindwalk Holdings Corp. overvalued?
According to Wall Street analysts Mindwalk Holdings Corp.’s price is currently Undervalued.
Does Mindwalk Holdings Corp. pay dividends?
Mindwalk Holdings Corp. does not currently pay dividends.
What is Mindwalk Holdings Corp.’s EPS estimate?
Mindwalk Holdings Corp.’s EPS estimate is -0.04.
How many shares outstanding does Mindwalk Holdings Corp. have?
Mindwalk Holdings Corp. has 46,711,864 shares outstanding.
What happened to Mindwalk Holdings Corp.’s price movement after its last earnings report?
Mindwalk Holdings Corp. reported an EPS of -€0.051 in its last earnings report, missing expectations of -€0.034. Following the earnings report the stock price went up 5.455%.
Which hedge fund is a major shareholder of Mindwalk Holdings Corp.?
Currently, no hedge funds are holding shares in DE:TQB0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MindWalk Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€4.28 (370.27% Upside)
€4.28 (370.27% Upside)
Blogger Sentiment
Bullish
DE:TQB0 Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $73.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
214.76%
12-Months-Change
Fundamentals
Return on Equity
-63.13%
Trailing 12-Months
Asset Growth
-46.01%
Trailing 12-Months
Company Description
Mindwalk Holdings Corp.
MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock therapeutic possibilities. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 2025. The company was incorporated in 1983 and is headquartered in Austin, Texas.
TQB0 Company Deck
TQB0 Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong commercial and scientific positives: robust revenue growth (Q3 +52% YoY, nine-month +45%), U.S. revenue doubling, the signing of the first enterprise recurring Lens AI platform contract, important preclinical pipeline discoveries (conserved dengue epitope, influenza conserved feature, GLP-1 activity vs semaglutide), peer-reviewed validation, and a new nanobody platform launch. Offsetting these strengths are higher operating expenses (notably S&M and R&D), a Q3 gross margin dip, ongoing net losses and cash burn ($10.1M YTD), and dependency on pending preclinical readouts and successful asset-level financing. Overall, the highlights—revenue acceleration, platform monetization, and differentiated scientific milestones—materially outweigh the lowlights tied to investment-driven losses and program-stage risk.View all DE:TQB0 earnings summariesTQB0 Stock 12 Month Forecast
Average Price Target
€4.28
▲(370.27% Upside)
Technical Analysis
XBiotech
―
Relmada Therapeutics
―
PMV Pharmaceuticals
―
Werewolf Therapeutics
―
Estrella Immunopharma
―
Options Prices
Currently, No data available
---